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be the critical receptor for SAA3 during
the inflammatory-like response in the pre-
metastatic niche. Moreover, while primary
tumor cell growth was not impaired by the
absence of TLR4, deletion of this receptor
both dramatically decreased the number
of metastatic tumor sites and reduced
the engraftment of Mac1+ myeloid cells
in those sites. Additionally, Mac1+ cell re-
cruitment to future metastatic sites was
impaired in TLR4/ mice, suggesting
that Toll-like receptor signaling may play
a critical role in the crosstalk between tu-
mor cells and BMDCs during premeta-
static niche formation. Finally, inhibition
of SAA3 function by neutralizing anti-
bodies abolished cell migration to preme-
tastatic lung sites by blocking the recruit-
ment of both BMDCs and tumor cells,
indicating that interfering with SAA3-
TLR4 signaling may have a therapeutic
benefit in delaying or preventing tumor
metastasis.
Taken together, these data shed new
light on the molecular mechanisms of
premetastatic niche formation and sug-
gest that this process is analogous to an
inflammatory nidus. However, many
questions still remain. For example, why
does SAA3-TLR4 signaling promote the
expression of inflammatory chemoattrac-
tants in some specific tissue types (such
as lung) but not others? Furthermore,
there may also be as yet unrecognized in-
teractions between these cells and other
inflammatory cells such as lymphocytes
and fibroblasts, and also changes in the
extracellular matrix. It is unclear what
role other Toll-like receptors may play in
the premetastatic phase, not only on im-
mune cells but also on tumor cells, where
they may influence tumor growth and
host immune responses (Huang et al.,
2008). It is also unclear from this study
whether the proinflammatory cytokine
TNFa can act independently from the
SAA3-TLR4 and NF-kB pathways as
shown recently by Oguma et al. (2008).
These differences may emphasize the
variations in the molecular events occur-
ring during development of the primary
tumor and during the establishment of
metastatic disease.
Although there aremanymore details to
be unraveled, Hiratsuka et al. have made
great strides toward describing the earli-
est stages in metastasis formation, un-
covering important roles for inflammatory
signaling pathways such as p38 and NF-
kB in premetastatic niche formation and
in recruitment of both supportive BMDCs
and disseminating cancer cells. These ad-
ditional clues could be used to develop
new and much-needed therapeutic strat-
egies to prevent organ-specific meta-
static spread.
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Switching between elongated and roundedmodes of movement allows invasive tumor cells to adapt to vary-
ing microenvironments. In a recent issue of Cell, Sanz-Moreno et al. identify DOCK3, NEDD9, WAVE2, and
ARHGAP22 as keymolecules regulating Rac and Rho signaling that determine themode ofmovement driving
melanoma cell metastasis.
Two properties that differentiate malig-
nant cancer from benign are local tissue
invasion by tumor cells and metastasis
to sites separate from the primary tumor.
In fact, metastasis is the main factor ac-
counting for cancer treatment failure and
is responsible for 90% of cancer deaths
(Hanahan and Weinberg, 2000). Due to
the significant impact that invasion and
metastasis have on cancer mortality, in-
tense research effort is directed at deter-
mining the critical molecular components
involved, in the hope that this knowledge
will eventually improve diagnosis and
treatment (Olson and Sahai, 2008).
In vivo, tumor cells must break away
from the primary cell mass, move through
tissues by deforming and/or degradingCancer Cell 14, November 4, 2008 ª2008 Elsevier Inc. 349
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PreviewsFigure 1. Switching between Elongated and Rounded Modes of Tumor Cell Movement
Reciprocal inhibitory crosstalk between Rac and Rho GTPases determines elongated or rounded modes
of movement of cancer cells. Elongated (‘‘mesenchymal’’) cell movement is driven by activation of Rac1 by
a NEDD9/DOCK3 complex and consequent WAVE2-mediated actin polymerization. WAVE2 also re-
presses actin-myosin contractility and inhibits rounded (‘‘amoeboid’’) cell movement. In contrast, RhoA
and ROCK activation lead to elevated actin-myosin contractility that promotes rounded cell movement
and suppresses Rac1-dependent elongated movement by activating the ARHGAP22 RacGAP.the extracellular matrix (ECM), cross tis-
sue boundaries, and in the case of meta-
static cells, travel via lymphatic or blood
vessels to establish secondary tumors.
Although modeling the complexities of
the in vivo environment is a challenge, it
is critically important that the models
used resemble the genuine situation as
closely as possible. The study of invasion
and metastasis has been somewhat
compromised by inadequate in vitro
models; by definition, these processes
occur in complex three-dimensional envi-
ronments, yet cell motility has traditionally
been studied using tissue culture cells
grown in conditions that restrict move-
ment to two dimensions. Not only does
this overlook the importance of ECM re-
modeling, two-dimensional motility is the
product of a single mechanistic mode in
which actin polymerization at the leading
edge propels the cell forward.
In a three-dimensional environment, the
protrusive force of actin polymerization
drives cells into an elongated, or ‘‘mesen-
chymal,’’ morphology that is sufficient to
push through the ECM only in the pres-
ence of protease activity to degrade the
ECM (Figure 1) (Wolf et al., 2003; Sahai350 Cancer Cell 14, November 4, 2008 ª20and Marshall, 2003). However, a second
mode of motility may be observed in
a three-dimensional context in which cells
adopt a roundedmorphology and migrate
through the ECM by an ‘‘amoeboid’’ form
of movement using actin-myosin contrac-
tile force to generate bleb-like protrusions
that push and squeeze cells through the
ECMwithout the need for proteolysis (Fig-
ure 1). Tumor cells can be classified into
those that predominantly take on an elon-
gated morphology, a rounded morphol-
ogy, or a mixture of both. The tendency
to adopt one specific mode or a mixture
of modes is likely due to cell-intrinsic
properties. Importantly, these two modes
of motility have been observed in invading
tumor cells in vivo (Wyckoff et al., 2006),
and tumor cells may switch between the
elongated and rounded modes of move-
ment in an adaptive response to the
microenvironment (Wolf et al., 2003; Sahai
and Marshall, 2003). This plasticity allows
cells to utilize the mode of movement
most favorable to the conditions encoun-
tered as theymove away from the primary
tumor.
The elongated mode of movement is
dependent on Rac activation, which sig-08 Elsevier Inc.nals to multimolecular protein complexes
that promote the nucleation and elonga-
tion of actin filaments. In contrast, amoe-
boid movement is driven by actin-myosin
contractility mediated by RhoA and its
effector proteins ROCKI and ROCKII.
Rac andRho activities aremutually antag-
onistic: active Rac represses Rho activity
and vice versa. The conversion to an
active GTP-bound form is promoted by
Rho guanine nucleotide exchange factors
(RhoGEFs), while inactivation to the GDP-
bound form is catalyzed by Rho GTPase-
activating proteins (RhoGAPs) (Bos et al.,
2007). Although the number of Rho
GTPases is relatively modest (22), the
number of RhoGEFs and RhoGAPs is
far in excess of their target proteins. The
multitude of Rho and Rac regulators has
made it difficult to identify which are
the central players in specific contexts
and to determine the mechanisms of
crosstalk between Rho and Rac signaling
pathways.
In order to identify key proteins regulat-
ing tumor cell morphology and move-
ment, Sanz-Moreno et al. (2008) used
siRNA to screen for important RhoGEFs
and RhoGAPs. A complex containing the
DOCK3 RhoGEF, along with the adaptor
protein NEDD9, was required for activa-
tion of Rac and consequent elongated
movement. Interestingly, Rac acting via
WAVE2 was found to repress phosphory-
lation of regulatory myosin light chain 2
(MLC2), with the consequent effect of
suppressing amoeboid movement. Pre-
cisely how Rac andWAVE2, a component
of a multiprotein complex that promotes
actin polymerization, reduce MLC2 phos-
phorylation remains to be determined. In
a reciprocal manner, during amoeboid
movement, RhoA signaling through
ROCK to promote actin-myosin contrac-
tility results in the repression of Rac activ-
ity via ARHGAP22 to suppress elongated
motility. This reciprocal inhibitory cross-
talk effectively increases the signal gain
in favor of either specific Rho-type or
Rac-type behaviors, thereby creating a bi-
stable switch that turns on either one
mode of movement or the other. This
property is important because it means
that as tumor cells move and encounter
a series of graded variables, the response
will be an either/or choice and not an un-
coordinated mixture of actin cytoskeleton
rearrangements. Some tumor cells may
be hardwired (e.g., elevated NEDD9; Kim
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Previewset al., 2006) to stick with a particular mode
of movement irrespective of the external
environment, but in general, the ability to
switch between modes of movement
gives cells the greatest chance to react
to a broad and changeable range of con-
ditions.
Although Sanz-Moreno et al. (2008)
have made a number of important discov-
eries, their findings also raise additional
questions. Given the large number of
RhoGEFs and RhoGAPs, it is notable
that DOCK3/NEDD9 and ARHGAP22 are
sufficient for Rac activation and inactiva-
tion, respectively. It remains to be deter-
mined whether these proteins also con-
tribute to the movement of other types of
tumor cells. RhoA is highly active in the
amoeboid mode of movement, but the
RhoGEF (or multiple RhoGEFs) responsi-
ble has yet to be identified. More chal-
lenging will be working out the mecha-
nisms responsible for the inhibition of
Rac activity by Rho signaling and vice
versa. Although ROCK activation was suf-
ficient to repress Rac activity, this does
not appear to work via direct phosphory-
lation of ARHGAP22 by ROCK; instead,
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Dogma held that inhibition of the ple
cinogenic due to its natural repress
kemias, possibly paving the way fo
Glycogen synthase kinase-3 (GSK-3)
was originally identified and later en-
shrined as a member of the insulin-sig-
naling pathway responsible for phos-
phorylation and inactivation of glycogen
synthase, a major regulatory enzyme of
glycogen metabolism. But it was soon
recognized that this kinase paints with
far broader strokes, influencing pro-ARHGAP22-mediated inactivation of Rac
by unknownmeans. Similarly, the locus of
WAVE2-mediated repression of MLC2
phosphorylation has not been identified;
although regulation of RhoA activity
seems most likely, it is also possible that
the effect occurs directly on MLC2. Given
that WAVE2 is a single component of
a large multiprotein complex, it will be in-
teresting to determine whether this effect
ismediated by the individual protein or the
entire WAVE2 complex. It has recently
been shown that depletion of the WAVE
complex protein Brk1 induces blebbing,
suggesting that a functional complex is
required for RhoA suppression (Derivery
et al., 2008).
These observations also impact upon
potential antimetastatic drug therapies—
if one mode of motility is targeted, for
example by inhibiting protease or ROCK
activity, then tumor cells may switch to
the other mode. Therefore, it would be de-
sirable to target proteins that may contrib-
ute to both modes of movement, for ex-
ample LIM kinases (Scott and Olson,
2007), to increase the likelihood of suc-
cessfully blocking the spread of cancer
cells.e Kinase-3 and Ca
op?
o, ON M5G 1X5, Canada
iotropic protein kinase glycogen synt
ion of b-catenin. Now, Wang et al. ha
r small-molecule GSK-3 inhibitors as
cesses that govern cell metabolism, po-
larity, transcription, cell-cycle division,
apoptosis, development, and cell fate. In
mammals, GSK-3 exists as two isoforms,
encoded by separate genes. GSK-3a
(51 kDa) and GSK-3b (47 kDa) are highly
conserved and widely expressed kinases
that share 98% sequence identity within
their catalytic domains (Doble and Wood-
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hase kinase-3 (GSK-3) was procar-
ve found the reverse in certain leu-
selective anticancer agents.
gett, 2003). While structurally related,
these isoforms are not functionally equiv-
alent.
Unlike most protein kinases, GSK-3 is
active under resting conditions and is rap-
idly inhibited by diverse stimuli. For exam-
ple, insulin, via PI3K/Akt/PKB, induces the
inactivation of GSK-3. Many of its cellular
targets are held in an inactive state
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